For Investors

Corporate Profile
AVEO Oncology is a biopharmaceutical company committed to discovering and developing targeted therapies designed to provide substantial impact in the lives of people with cancer by addressing unmet medical needs. AVEO’s proprietary Human Response Platform provides the company unique insights into cancer and related disease biology and is being leveraged in the discovery and clinical development of its therapeutic candidates.
Stock Quote
AVEO (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Up 0.01 (0.96%)
Data as of 10/22/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent Press Releases 
09/29/14AVEO Oncology Announces Results from Phase 2 Clinical Studies of Tivozanib in Patients with Advanced Colorectal and Kidney Cancers Presented at ESMO 2014 Congress
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 29, 2014-- AVEO Oncology (NASDAQ:AVEO) today announced poster presentations for two Phase 2 clinical studies of tivozanib, one in metastatic colorectal cancer (mCRC) and one in renal cell carcinoma (RCC), at the 2014 Congress of the European Society for Medical Oncology (ESMO), taking place September 25–30 in Madrid, Spain. Tivozanib is an oral, potent, selective inhibitor of vascular endothelial growth factor tyro... 
Printer Friendly Version
09/29/14AVEO and Biodesix Announce Exploratory Analysis of VeriStrat-Selected Patients with Non-Small Cell Lung Cancer in Phase 2 Study of Ficlatuzumab Presented at ESMO 2014 Congress
VeriStrat “Poor” Patients Show Encouraging Overall Survival and Progression Free Survival Signal; Confirmatory Phase 2 Study Planned by Year-End MADRID--(BUSINESS WIRE)--Sep. 29, 2014-- AVEO Oncology (NASDAQ:AVEO) and Biodesix, Inc. today announced the presentation of results from a retrospective exploratory analysis using VeriStrat®, a commercially available serum protein test, to identify patients most likely to benefit from the addition of ... 
Printer Friendly Version
09/26/14AVEO Oncology Announces Presentation of AV-380 Preclinical Data at 2nd Cancer Cachexia Conference
MONTREAL--(BUSINESS WIRE)--Sep. 26, 2014-- AVEO Oncology (NASDAQ:AVEO) today announced the presentation of results from four preclinical studies of AV-380, the Company’s potent, humanized inhibitory antibody targeting growth differentiation factor 15 (GDF15), in various in vivo cachexia models and in vitro assays at the 2nd Cancer Cachexia Conference, being held September 26-28, 2014, in Montreal, Canada. In addition to the poster presentations, t... 
Printer Friendly Version
More Press Releases >>
Upcoming Events 
There are currently no events scheduled.
More Events >>
Phase 2 clinical evaluation of preclinically defined biomarkers for vascular endothelial growth factor tyrosine kinase inhibitor tivozanib in renal cell carcinoma
BATON-CRC: a phase 2 randomized trial comparing tivozanib + mFOLFOX6 with bevacizumab + mFOLFOX6 in stage IV metastatic colorectal cancer
Efficacy analysis of gefitinib +/- ficlatuzumab in serum proteomic-based subgroups of patients with previously untreated lung adenocarcinoma
First in human Phase 1 dose-escalation study of AV-203; #395, J. Sarantopoulos
AACR 2014, Cancer Cachexia Poster #1441, Liu
More Presentations >>

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.